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Abstract
Purpose Dexamethasone, plus a 5-HT3 receptor antagonist
and an NK-1 receptor antagonist are recommended for con-
trolling the chemotherapy-induced nausea and vomiting
(CINV) of highly emetogenic chemotherapy. Several days of
dexamethasone are effective for CINV; however, dexametha-
sone also has side effects. The purpose of this trial was to
investigate whether the use of a second-generation 5-HT3
receptor antagonist and an NK-1 receptor antagonist could
allow a reduced dose of dexamethasone for breast cancer pa-
tients receiving highly emetogenic chemotherapy.
Methods Eighty breast cancer patients who received an
anthracycline-cyclophosphamide combination regimen were
enrolled. The patients were randomized to arm A (dexameth-
asone days 1–3) and arm B (dexamethasone day 1). The pri-
mary endpoint was complete response (CR) (no emetic epi-
sodes and no rescue medication) during the overall phase
(days 1–5). The secondary endpoints were the CR during the
delayed phase (days 2–5), complete control (CC) (no emetic
episodes, no rescue medication, and no more than mild nau-
sea) during the overall phase, and the safety of this antiemetic
therapy.
Results There were no significant differences in the rates of
CR and CC between arm A and B as follows: CR overall
phase—arm A: 82.9 %, 90 % confidence interval [CI] 71.3–
90.5 % vs arm B: 82.1 %, 90 % CI 70.0–90.0 %; p=1.00; CR
delayed phase—arm A: 87.8 %, 90 % CI 77.0–93.9 % vs arm
B: 94.9 %, 90 % CI 85.6–98.3 %; p=0.43; CC overall
phase—arm A: 48.8 %, 90 % CI 36.4–61.3 % vs arm B:
61.5 %, 90 % CI 48.4–73.2 %; p=0.27. There were very
few adverse events and no severe adverse events associated
with this antiemetic therapy.
Conclusions The results suggest that the antiemetic effect pro-
vided by dexamethasone administered for 3 days can be ob-
tained by dexamethasone administered for 1 day.
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Introduction
Chemotherapy-induced nausea and vomiting (CINV) is a ma-
jor nonhematologic toxicity associated with chemotherapy.
CINV not only affects quality of life but also compliance with
chemotherapy [1]. CINV varies, depending on the type, dos-
age, and route of administration of the antineoplastic agent.
Chemotherapy regimens have been classified according to the
incidence of nausea. A regimen associated with emesis in
≥90 % of patients was considered to have high emetic risk
(highly emetogenic chemotherapy [HEC]); with emesis in
30 to 90 % of patients, a moderate emetic risk (moderately
emetogenic chemotherapy [MEC]); with emesis in 10 to 30%
of patients, a low emetic risk; and with emesis in fewer than
10 % of patients, a minimal emetic risk [2, 3]. A chemother-
apy regimen for breast cancer containing an anthracycline
such as doxorubicin and epirubicin in combination with
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cyclophosphamide is classified as HEC. Based on the
antiemesis guidelines of the National Comprehensive Cancer
Network (NCCN, www.nccn.org), the American Society for
Clinical Oncology (ASCO) [4], and the Multinational Asso-
ciation for Supportive Care in Cancer (MASCC, www.mascc.
org), the recommended treatment for preventing CINV
associated with HEC is palonosetron, a serotonin (5-HT3)
receptor antagonist; aprepitant, a neurokinin 1 (NK-1) antag-
onist; and dexamethasone.
Palonosetron is a second-generation 5-HT3 receptor antag-
onist. It has a higher binding affinity to 5-HT3 receptors [5]
and a longer elimination half-life than the first-generation an-
tagonists. Palonosetron has been found to provide better con-
trol of CINV during the acute and delayed phases than the
first-generation 5-HT3 receptor antagonists [6, 7].
Dexamethasone administration is recommended until day
4 of treatment by the NCCN guidelines to prevent delayed
phase emesis. However, frequent steroid administration dur-
ing chemotherapy is associated with problematic side effects
such as edema, bulimia, weight gain, digestive disorders,
moon face, hyperglycemia, and reactivation of hepatitis B
virus [8–10]. Reducing the dose of steroids with resulting
reduction in side effects may be beneficial for patients under-
going chemotherapy. To the best of our knowledge, there have
not been any reported studies on the use of aprepitant and
palonosetron to decrease the dose of dexamethasone. The
aim of this study was to evaluate the antiemetic effects of
palonosetron and aprepitant combined with 1 day of dexa-
methasone administration. This was a single-blind, single-
center randomized controlled phase II trial of breast cancer




The patients who were eligible for inclusion were
chemotherapy-naive female patients with histologically con-
firmed breast cancer, ≥20 years of age, and scheduled to re-
ceive an anthracycline-cyclophosphamide combination regi-
men. Additional inclusion criteria included Eastern Coopera-
tive Oncology Group (ECOG) performance status 0–1, ade-
quate general condition (white blood cell count 3×109 cells/
L), hepatic function (aspartate aminotransferase [AST] and
alanine aminotransferase [ALT]<100 U/L), and renal function
(creatinine clearance ≥60 mL/min).
Exclusion criteria
Exclusion criteria included seizure disorder needing anticon-
vulsants, unless clinically stable; any vomiting, retching, or
grade 2 or higher nausea according to the National Cancer
Institute Common Terminology Criteria for Adverse Events
(NCI CTCAE); asymptomatic metastases to the brain; known
hypersensitivity to palonosetron, aprepitant or dexamethasone
ingredients; pregnancy/breast-feeding; receiving any drug
with antiemetic effects; and receiving pimozide. Patients were
also excluded if they were unable to cooperate or judged by an
investigator to be unfit for participation in the study.
Chemotherapy
The patients received the following regimens: FEC (5FU 500–
600 mg/m2, epirubicin 100 mg/m2, and cyclophosphamide
500–600 mg/m2), EC (epirubicin 75 mg/m2 and cyclophos-
phamide 600 mg/m2), or AC (doxorubicin 60 mg/m2 and cy-
clophosphamide 600 mg/m2).
Study design and treatment schedule
This was a phase II, single-center, single-blind, placebo-con-
trolled, parallel, randomized trial. Patients were randomized in
a 1:1 ratio using a minimization method, with stratification
into either arm A or arm B at the first cycle of chemotherapy.
The patients in arm A received palonosetron (0.75 mg intra-
venously) plus dexamethasone (12 mg intravenously) and
aprepitant (125 mg orally) on day 1, followed by dexametha-
sone (8 mg intravenously) and aprepitant (80 mg orally) on
days 2 and 3. The patients in arm B received saline (as place-
bo, intravenously) instead of dexamethasone on days 2 and 3.
Palonosetron, dexamethasone, and placebo were each dis-
solved in 50 mL of saline solution that was administered in-
travenously. The stratification factors included age (<50 years
or ≥50 years) and type of HEC (FEC or AC/EC). To evaluate
the efficacy endpoints of this study, every patient stayed for a
minimum of 5 days in our hospital.
Assessments
The primary endpoint of this study was the proportion of
patients with a complete response (CR), which was defined
as no emetic episodes and no rescue medication during the
overall phase (days 1–5). Secondary endpoints included the
proportion of patients with a complete response during the
delayed phase (days 2–5), the proportion of patients with com-
plete control (CC: no emetic episodes, no rescue medication,
and no more than mild nausea) during the overall phase, and
the safety of these antiemetic therapies. The severity of nausea
was categorized as none, mild, moderate, or severe, based on
the subjective assessment of each patient. Any episode of
nausea and vomiting was recorded in a diary contained in each
patient self report. Investigators also assessed the number of
emetic episodes and use of rescue medication by examining
each patient’s nursing records. Adverse events and
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concomitant medication were recorded during the 5 days.
Drug-related adverse events were classified according to
NCI CTCAE, version 4.0. The full analysis set included all
registered patients except those who were deemed ineligible
after registration and those who withdrew their agreement.
The endpoints were analyzed using the full analysis set. This
study was performed according to the guidelines of the Dec-
laration of Helsinki, as amended in Edinburgh, Scotland in
October 2000. Institutional review board approval and written
informed consents from the patients were obtained before any
specific study procedures were begun.
Statistical analysis
A previous phase 3 clinical trial (PROTECT) found that the
CR rate for palonosetron and dexamethasone 3 days treatment
during the overall phase was 51.5 % [11]. Grote et al. has
reported that the CR rate for palonosetron and dexamethasone
and aprepitant treatment was 78 % [12]. Herrington et al. has
reported that the CR rate was increased from 31.2 to 51.9 %
when aprepitant was added to palonosetron and dexametha-
sone treatment [13]. Thus, the additional effect contributed by
aprepitant was approximately 20 % [12–15]. Assuming a
threshold CR rate of 50 % based on the previous study, an
expected CR rate of 70 %, and with a one-sided α=0.05 and
β=0.20, we calculated that each arm required 36 patients.
Predicting that approximately 10 % of all patients would be
excluded or withdrawn from the study, we determined that at
least 40 patients were needed per arm.
A 90% confidence interval (CI) was determined for the CR
and CC rates. Comparisons were performed using a two-sided
chi-square test. In addition to determining the CR rates of each
treatment arm, subgroup analysis was performed to determine
stratified CR rates during the overall phase.
JMP software (SAS Institute Inc., Cary, NC, USA) was
used for statistical analysis. Statistical significance was con-
sidered to be p<0.05.
Results
Patient characteristics (Table 1)
From April 2011 to June 2013, a total of 82 breast cancer
patients treated at our hospital were enrolled in this trial. Two
patients were excluded from the full analysis set. One patient
had received previous chemotherapy, and the other patient
withdrew her agreement to participate. The overview of pa-
tient characteristics is shown in Table 1. Forty one patients
Table 1 Patient’s characteristics
of the study population Dexamethasone day 1–3 Dexamethasone day 1
(n=41) (n=39)
n % n %
Age (years) Mean (SD) 53.5 (10.9) 52.6 (10.4)
Range 35–76 37–67
<50 17 41.5 18 46.2
≥50 24 58.5 21 53.8
ECOG Performance status 0/1 40/1 39/0
Height (m) Mean (SD) 1.56 (0.05) 1.55 (0.06)
Body weight (kg) Mean (SD) 58.7 (13.1) 56.3 (10.3)
Body surface area (m2) Mean (SD) 23.9 (4.42) 23.3 (3.99)
Alcohol consumption Yes 16 39.0 14 35.9
No 25 61.0 25 64.1
Smoking Yes 10 24.4 4 10.3
No 31 75.6 35 89.7
Chemotherapy Neoadjuvant or Adjuvant 38 92.7 36 92.3
Metastatic 3 7.3 3 7.7
Regimen AC 4 9.8 1 2.6
EC 13 31.7 14 35.9
FEC 24 58.5 24 61.5
SD standard deviation, ECOG Eastern Cooperative Oncology Group, AC doxorubicin and cyclophosphamide,
EC epirubicin and cyclophosphamide, FEC 5FU epirubicin and cyclophosphamide
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were assigned to arm A, and 39 patients were assigned to arm
B. The characteristics of the patients were balanced between
the groups.
Complete response (Fig. 1a)
The overview of CR and CC is shown in Fig. 1. CRs for the
overall phase were observed in 34/41 (82.9 %, 90 % CI 71.3–
90.5 %) patients of arm A and 32/39 (82.1 %, 90 % CI 70.0–
90.0 %; p=1.00) patients of arm B. CRs for the delayed phase
were 36/41 (87.8 %, 90 % CI 77.0–93.9 %) patients of arm A
and 37/39 (94.9 %, 90% CI 85.6–98.3 %; p=0.43) patients of
arm B.
Complete control (Fig. 1b)
CCs for the overall phase were observed in 20/41 (48.8 %,
90 % CI 36.4–61.3 %) patients of arm A and 24/39 (61.5 %,
90 % CI 48.4–73.2 %; p=0.27) patients of arm B.
Complete responses in overall phase (subgroup analysis)
Among the younger patients (<50 years, n=35), the CRs of
arms A and B were 13/17 (76.5 %) and 14/18 (77.8 %), re-
spectively (p=1.00) (Fig. 2a). The CRs of the older patients
(≥50 years, n=45) of arms A and B were 21/24 (87.5 %) and
18/21 (85.7 %), respectively (p=1.00) (Fig. 2a). The CRs of
patients undergoing the AC/EC regimen (n=32) of arms A
and B were 16/17 (94.1 %) and 12/15 (80.0 %), respectively
(p=0.32) (Fig. 2b). The CRs of patients undergoing the FEC
regimen (n=48) of arms A and B were 18/24 (75.0 %) and 20/
24 (83.3 %), respectively (p=0.72) (Fig. 2b).
Complete responses according to patient characteristics
The CRs for the overall phase of the younger and older pa-
tients were 27/35 (77.1 %) and 39/45 (86.7 %), respectively
(p=0.38) (Fig. 3a). The CRs for the overall phase of the
Fig. 1 The relationship between the complete response rates and
between the complete control rates of patients receiving dexamethasone
days 1–3 (arm A) and patients receiving dexamethasone day 1 only (arm
B). Two-sided chi-square test
Fig. 2 The relationship between the complete response rates of patients
receiving dexamethasone days 1–3 (arm A) and patients receiving
dexamethasone day 1 only (arm B), subgroup analyses. Two-sided chi-
square test. Patients were stratified by (a) age, and (b) type of
chemotherapy. AC anthracycline and cyclophosphamide, EC epirubicin
and cyclophosphamide, FEC 5FU, epirubicin, and cyclophosphamide
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patients undergoing the AC/EC and FEC regimenswere 28/32
(87.5 %) and 38/48 (79.2 %), respectively (p=0.92) (Fig. 3b).
Safety
There were very few adverse events associated with either
antiemetic regimen. Grade1 erythema was observed on the
face of one patient in arm A after dexamethasone was infused.
One patient in arm A had grade 1 generalized fatigue that
might have been associated with chemotherapy. One patient
in arm B had grade 1 headache, and 1 patient in arm B had
grade 1 constipation. No severe adverse events attributed to
antiemetic therapy were seen. Clinically abnormal laboratory
values (white blood cell counts, neutrophil counts, platelet
counts, hemoglobin, AST, ALT) that were attributed to che-
motherapy developed in 73 patients.
Discussion
This study was the first phase II trial of breast cancer patients
who received an HEC regimen and aprepitant and
palonosetron. The trial evaluated the differences in the anti-
emetic effects of steroids administered for the standard dura-
tion and for a shorter duration of time. If no differences were
seen in the antiemetic effects, the results would indicate that
steroids could be administered for a shorter time, thereby re-
ducing the side effects associated with steroids. The results
show that the primary endpoints, CR for the overall phase,
were equivalent (arm A: 82.9 %, 90 % CI 71.3–90.5 % vs
arm B: 82.1 %, 90 % CI 70.0–90.0 %, p=1.00). On the day of
chemotherapy (day 1), conditions for both groups were the
same, and a difference in the delayed phase was expected.
However, the CR rates for the delayed phase were also equiv-
alent (armA; 87.8 %, 90%CI 77.0–93.9 % vs arm B; 94.9 %,
90 % CI 85.6–98.3 %, p=0.43).
Aapro et al. verified that 1 day of dexamethasone adminis-
tration for breast cancer patients receiving chemotherapy was
adequate [16]. They carried out a double-blind, randomized
controlled study of 300 patients who received cyclophospha-
mide and/or anthracycline together with palonosetron
(0.25 mg), with one arm receiving dexamethasone on day 1
and the other arm receiving dexamethasone on days 1–3. The
results showed that the antiemetic effects were equivalent.
They concluded that a 3-day regimen of steroids was not nec-
essary when the second-generation 5-HT3 receptor antagonist
palonosetron was administered. The overall CR rate was
53.6 % for the arm receiving dexamethasone on day 1 and
53.7% for the arm receiving dexamethasone on days 1–3. The
overall CR rates were higher in our study than in the Aapro
study. Moreover, the CR rates of the acute and delayed phase
were also higher in our study than the rates in the Aapro study.
We think that the differences in CR rates might be attributed to
the aprepitant therapy that was administered to our study pa-
tients. Another possible reason for the differences might be the
differences in insurance-approved doses of palonosetron
(0.75 mg in Japan vs 0.25 mg in other countries).
Regarding antiemetic treatments for the MEC regimens,
Damien et al. carried out a single-arm phase II trial of 79 breast
cancer patients who received AT (anthracycline, paclitaxel),
palonosetron (0.25 mg), and steroids on day 1 only [17]. They
found equivalent CC rates for the acute and delayed phases
(77.6 and 73.7%, respectively). Celio et al. carried out a phase
III trial of 332 patients that included patients with breast can-
cer who received AC and palonosetron (0.25 mg) plus dexa-
methasone for 1 day or for 3 days [18]. The difference in the
overall CR rates of those receiving dexamethasone for 1 or
Fig. 3 The relationship between the complete response rates of patients
receiving dexamethasone days 1–3 (arm A) and patients receiving
dexamethasone day 1 only (arm B), patient’s characteristics analyses.
Two-sided chi-square test. Patients were stratified by (a) age, and (b) type
of chemotherapy. AC anthracycline and cyclophosphamide, EC
epirubicin and cyclophosphamide, FEC 5FU, epirubicin, and
cyclophosphamide
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3 days was not significant. The results of these trials suggest
that with the administration of palonosetron during an MEC
regimen, CINV can be controlled by 1 day of steroid admin-
istration.Moreover, Celio et al. performed a subgroup analysis
[19]. Multivariate analysis determined that age younger than
50 years was a risk factor for CINV. The NCCN guidelines
reported that the occurrence of acute emesis is affected by age
and gender (female and younger patients [age<50 years] are
more prone to emesis). Our study found that there was no
significant difference in the CRs of the younger and older
patients (Fig. 3a).
In our study, the CC rates for the overall phase of arms A
and B were 48.8 and 61.5 %, respectively. The CC rates were
secondary endpoints, and the difference between arms A and
B was not significant. However, the CC rate of arm B tended
to be higher. The insignificant difference might be associated
with the small sample and the fact that this was a subjective
patient assessment.
The guidelines of the European Society of Medical Oncol-
ogy, MASCC, ASCO, NCCN, and Japan Society of Clinical
Oncology recommend that steroids be administered over sev-
eral days to control CINVassociated with HEC (www.jsco.or.
jp) [20]. Although there were no severe adverse events due to
steroid administration in our study, we think that for patients
where CINV control is possible with aprepitant and
palonosetron, decreased steroid use may be beneficial.
Steroids should only be administered after considering their
efficacy and side effects.
The results suggest that the antiemetic effect provided by
dexamethasone administered for 3 days can be obtained by
dexamethasone administered for 1 day for breast cancer pa-
tients who receive an HEC regimen. The small sample size
was a major limitation of this study. However, we believe that
a phase III study examining the utility of the 1 day dexameth-
asone treatment is warranted.
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